Published in Arthritis Res Ther on August 15, 2011
Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative. Arthritis Rheumatol (2015) 2.07
Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. PLoS One (2017) 1.39
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) (2014) 1.34
Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med (2012) 1.13
Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol (2015) 1.11
Helminth infection in populations undergoing epidemiological transition: a friend or foe? Semin Immunopathol (2012) 1.01
The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One (2015) 0.95
Monitoring diabetes in patients with and without rheumatoid arthritis: a Medicare study. Arthritis Res Ther (2012) 0.94
The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis (2015) 0.92
Study of association of CD40-CD154 gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients. PLoS One (2012) 0.91
Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care. Arthritis Care Res (Hoboken) (2014) 0.91
Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore) (2015) 0.89
CARD8 rs2043211 (p.C10X) polymorphism is not associated with disease susceptibility or cardiovascular events in Spanish rheumatoid arthritis patients. DNA Cell Biol (2012) 0.88
Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther (2014) 0.87
Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol (2013) 0.87
Contractile, but not endothelial, dysfunction in early inflammatory arthritis: a possible role for matrix metalloproteinase-9. Br J Pharmacol (2012) 0.85
The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther (2014) 0.84
Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis. J Immunol Res (2015) 0.82
Cardiovascular involvement in autoimmune diseases. Biomed Res Int (2014) 0.82
Co-morbidity in patients with early rheumatoid arthritis - inflammation matters. Arthritis Res Ther (2016) 0.82
Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther (2016) 0.82
Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Res Ther (2016) 0.81
Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep (2012) 0.81
Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort. BMC Musculoskelet Disord (2013) 0.81
Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. Expert Rev Clin Immunol (2012) 0.80
Decreased heart rate variability in patients with psoriatic arthritis. Clin Rheumatol (2012) 0.78
Renal "hyperfiltrators" are at elevated risk of death and chronic diseases. BMC Nephrol (2014) 0.78
Lack association of body mass index with disease activity composites of rheumatoid arthritis in Korean population: cross-sectional observation. Clin Rheumatol (2013) 0.78
Red cell distribution width: a measure of cardiovascular risk in rheumatoid arthritis patients? Clin Rheumatol (2015) 0.77
Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis? J Med Life (2015) 0.76
Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis (2016) 0.76
HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. Cardiovasc Diagn Ther (2016) 0.75
Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study. BMC Musculoskelet Disord (2016) 0.75
The Prevalence of Atherosclerosis in Those with Inflammatory Connective Tissue Disease by Race, Age, and Traditional Risk Factors. Sci Rep (2016) 0.75
Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS One (2017) 0.75
Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study. Mediators Inflamm (2015) 0.75
Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int (2016) 0.75
Anti-inflammatory effect of Pueraria tuberosa extracts through improvement in activity of red blood cell anti-oxidant enzymes. Ayu (2013) 0.75
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. PLoS One (2017) 0.75
Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep (2017) 0.75
[Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis]. Z Rheumatol (2012) 0.75
Prevalence of Asymptomatic Arterial Hypertension and Its Correlation with Inflammatory Activity in Early Rheumatoid Arthritis. Open Access Maced J Med Sci (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
The mortality of rheumatoid arthritis. Arthritis Rheum (1994) 6.18
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum (2005) 5.31
Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum (2005) 4.63
Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol (1997) 3.65
Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol (1988) 3.25
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther (2004) 2.72
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum (2009) 2.55
Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) (2006) 2.54
Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis (2007) 2.46
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther (2006) 2.28
HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.28
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther (2008) 2.15
High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum (2008) 2.14
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med (2002) 2.13
Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis (2005) 2.11
Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum (2005) 2.02
Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol (1995) 1.96
Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.91
Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med (2005) 1.77
High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol (2005) 1.72
Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum (2004) 1.67
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63
Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. J Rheumatol (2002) 1.56
PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther (2006) 1.51
Cachexia in rheumatoid arthritis. Int J Cardiol (2002) 1.47
Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol (2007) 1.45
Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.42
Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism (1988) 1.35
Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum (2008) 1.30
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med (1994) 1.30
Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum (2009) 1.23
Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum (2003) 1.20
The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther (2007) 1.20
Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis (2006) 1.18
Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis (1991) 1.15
The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol (2002) 1.07
Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med (1987) 1.06
Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis (2008) 0.92
Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol (2005) 0.88
Lipoprotein lipase in relation to inflammatory activity in rheumatoid arthritis. J Intern Med (1996) 0.83
Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol (2010) 0.83
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med (2008) 9.61
A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum (2006) 9.52
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet (2005) 4.80
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum (2009) 2.97
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis (2007) 2.53
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum (2005) 2.45
A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet (2008) 1.98
Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest (2005) 1.70
No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum (2009) 1.68
Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther (2011) 1.64
Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis (2010) 1.59
Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther (2010) 1.55
PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther (2006) 1.51
Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum (2013) 1.46
Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis (2011) 1.39
[Emergency medical services require stronger resources when it comes to internal medicine]. Lakartidningen (2002) 1.39
Selective IgA deficiency in autoimmune diseases. Mol Med (2011) 1.31
Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther (2011) 1.25
The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther (2007) 1.20
Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study. J Rheumatol (2012) 1.19
Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis (2006) 1.18
Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol (2002) 1.10
Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res Ther (2011) 1.09
Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. Eur J Hum Genet (2012) 1.09
Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol (2002) 1.06
CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis. Ann Rheum Dis (2009) 1.06
A candidate gene study of the type I interferon pathway implicates IKBKE and IL8 as risk loci for SLE. Eur J Hum Genet (2010) 1.01
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis (2013) 1.01
Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum (2012) 1.00
Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA (2012) 0.96
BDNF in RA: downregulated in plasma following anti-TNF treatment but no correlation with inflammatory parameters. Clin Rheumatol (2008) 0.95
Association of a PDCD1 polymorphism with renal manifestations in systemic lupus erythematosus. Arthritis Rheum (2005) 0.92
Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther (2005) 0.91
A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis (2009) 0.90
Unexpected finding of a marked non-neuronal cholinergic system in human knee joint synovial tissue. Neurosci Lett (2008) 0.89
Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study. Arthritis Res Ther (2014) 0.87
Polymorphisms of the genes encoding CD40 and growth differentiation factor 15 and in the 9p21.3 region in patients with rheumatoid arthritis and cardiovascular disease. J Rheumatol (2012) 0.86
Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum (2002) 0.86
Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford) (2010) 0.85
Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ Cardiovasc Genet (2013) 0.84
The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther (2014) 0.84
Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level. Rheumatology (Oxford) (2010) 0.82
T-cell expression of CD91 - a marker of unresponsiveness to anti-TNF therapy in rheumatoid arthritis. APMIS (2010) 0.81
Life satisfaction in early rheumatoid arthritis: a prospective study. Scand J Occup Ther (2006) 0.81
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study. BMJ Open (2012) 0.80
Preferential association of interferon regulatory factor 5 gene variants with seronegative rheumatoid arthritis in 2 Swedish case-control studies. J Rheumatol (2011) 0.80
Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases. J Clin Immunol (2002) 0.80
Association between the PTPN22 +1858 C/T polymorphism and psoriatic arthritis. Arthritis Res Ther (2011) 0.80
Modifiable cardiovascular risk factors in patients with ankylosing spondylitis. Clin Rheumatol (2013) 0.80
Measurements in the Blood of BDNF for RA Patients and in Response to Anti-TNF Treatment Help Us to Clarify the Magnitude of Centrally Related Pain and to Explain the Relief of This Pain upon Treatment. Int J Inflam (2011) 0.80
Novel information on the non-neuronal cholinergic system in orthopedics provides new possible treatment strategies for inflammatory and degenerative diseases. Orthop Rev (Pavia) (2009) 0.79
Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med (2007) 0.79
Metabolic responses to change in disease activity during tumor necrosis factor inhibition in patients with rheumatoid arthritis. J Proteome Res (2012) 0.79
Glucocorticoid treatment increases density of serotonin 5-HT2A receptors in humans. Psychoneuroendocrinology (2012) 0.78
Health-related quality of life in Swedish men and women with early rheumatoid arthritis. Gend Med (2009) 0.78
A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. Arthritis Res Ther (2015) 0.77
Plasma phospholipid fatty acid content is related to disease activity in ankylosing spondylitis. J Rheumatol (2011) 0.76
Diet, disease activity, and gastrointestinal symptoms in patients with ankylosing spondylitis. Clin Rheumatol (2010) 0.75
[Cardiovascular risk in inflammatory systemic disease should be assessed regularly. The Swedish Society of Rheumatology has formulated guidelines for primary prevention]. Lakartidningen (2012) 0.75
[Antibodies against cyclic citrullinated peptide indicate rheumatoid arthritis]. Lakartidningen (2009) 0.75
[Rheumatologic research with animal experiments is important for our patients]. Lakartidningen (2012) 0.75
Suppressed signal transduction in the bronchial epithelium of patients with systemic sclerosis. Respir Med (2008) 0.75
Oxygen saturation and cognitive performance. Psychopharmacology (Berl) (2002) 0.75